Funding, launches, leadership moves and hiring signals across the companies building the future of science and healthcare.
Choose a market to see its news feed and every edition of its newsletter.
Lab and R&D software, scientific data platforms, LIMS/ELN, AI for drug discovery and biotech SaaS.
Therapeutics across CNS, immunology & inflammation and beyond: clinical readouts, approvals, licensing and BD deals, and leadership moves at clinical- and commercial-stage pharma and biotech.
Emerging and clinical-stage biotech: financings, readouts, regulatory milestones and C-suite moves.
Genomics, molecular diagnostics, liquid biopsy, digital pathology and precision medicine.
Healthcare AI, revenue cycle management, prior authorisation and payer/provider technology.
Materials informatics, cheminformatics and R&D software for chemicals, CPG and advanced materials.
Hiring trends, layoffs, applicant markets, salary data and what’s working in talent acquisition across life sciences.
Community · Issy EadenA peer network of 60+ senior women across digital health, medtech and life sciences.
Headlines from across the division.
The Barcelona start-up behind the HER2DX breast cancer test joins Hologic's oncology diagnostics, alongside its Breast Cancer Index. Price not disclosed.
Read the full story →Fresh off selling Vega to Incyte and floating Electra, the team is restarting with a preclinical hematology and immunology pipeline. Janus Henderson says it rarely invests this early.
Read the full story →Reuters reports BASF has lifted its offer to €24 a share, about €11.18bn, and is pledging no compulsory redundancies until 2032.
Read the full story →$1.275bn upfront for Phase 1 HCXT-2001, days after its own oral IBD drug emvistegrast hit in Phase 2. An all-oral IBD combination is the plan.
Read the full story →Signing as self-funded employers, they're asking their insurers and TPAs to extend the pledge's electronic prior auth improvements to their own health plans.
Read the full story →27 companies cut 2,568 people, about 90% fewer than a year ago and the lowest quarter since BioSpace started tracking. New Jersey was hit hardest.
Read the source →Agents now run whole R&D workflows, with scientists approving key steps. Benchling calls agents its fastest-growing product.
Read the full story →Long reads will join its rare disease genome testing to catch structural variants and repeat expansions that short reads can miss. Early access is due by year-end.
Read the full story →Non-dilutive money for the Phase 1/2 trial of EPI-321, a one-time epigenetic therapy that silences DUX4 in FSHD without cutting DNA.
Read the full story →Evonik’s interest in the US specialty chemicals firm, valued at about $3.3bn, surfaced a day earlier. BASF reportedly sees it as too risky.
Read the full story →$20 per ADS, about $1.3bn in equity value, for divesiran in polycythemia vera. Merck KGaA's entry into haematology.
Read the full story →A CMS deputy administrator said “a lot of things” about the AI-assisted Medicare prior auth pilot running in six states are not working. Expect more scrutiny of AI-led denials.
Read the full story →Pick the markets you care about. Each is a three-minute weekly read, written by the QP Group specialist for that market. No spam, one-click unsubscribe.
